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Background:  Androgen deprivation therapy (ADT) for prostate cancer (PC) has been associated with adverse cardiovascular outcomes, 
including heart failure (HF). However, it is unclear whether ADT worsens pre-existing heart conditions or contributes to development of 
cardiac dysfunction and new-onset HF.
methods:  Patients diagnosed with PC during 2007-13 at a community-based healthcare system were divided into those who underwent 
ADT with gonadotropin-releasing hormone agonist and 1:1 propensity-matched with patients without ADT. Cox proportional hazards 
models were developed to examine ADT effects on HF outcomes, including clinical Dx of HF with reduced ejection fraction (HFrEF), HF 
with preserved EF (HFpEF), low left ventricular EF (<55%), diastolic dysfunction (DD) based on reported grades 1-4 or DD computed from 
E/A and E/e’ echo values. Single- (SM) and multi-variable full (FM) models and stepwise variable selection (SVS) procedures provided 
estimates of unadjusted and adjusted hazard ratios (HR) and predictors of outcome. Failure rates within 3-yr follow-up were computed 
using lifetable (actuarial) methods. Men with HF preceding PC diagnosis were excluded.
results:  A total of 1,306 men (653 matched-pairs) were included with mean age of 69.5 yr and a mean follow-up of 3.9 yr. Consistent 
across SM, FM and SVS, ADT represented a non-significant effect on HFrEF and HFpEF (P>0.10) but significantly influenced ventricular 
function (P<0.05). Instantaneous hazard of low LVEF was 3 times greater (SVS adjusted HR: 3.0 [1.2-7.4]; P=0.01), but mean number 
of days to HFrEF was 4,000 d later for ADT (6,900 d) than non-ADT men (2,980 d). Failure rates, respectively, were 0.46 vs. 0.47% at 3 
months, 1.9 vs. 1.1% at 1 year, and 6.1 vs. 3.9% at 3 years. Risk of DD was 2 times greater (SVS adjusted HR: 2.0 [1.2-3.3] but mean 
number of days to HFpEF was 1,500 d later for ADT-treated (6,341 d) than non-treated men (4,800 d). Failure rates, respectively, were 0.6 
vs. 0.8% at 3 months, 3.6 vs. 2.2% at 1 year and 14.3 vs. 6.8% at 3 years.
conclusion:  While ADT effects were not evident for HF outcomes based on clinical diagnosis, adverse effects of treatment were detected 
for systolic and diastolic function based on echo readings.
